Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited
Key Takeaways
- Zepbound is tirzepatide, an injectable FDA-approved dual GLP-1/GIP agonist with ~22.5% mean weight loss at 15 mg (SURMOUNT-1)
- Orforglipron is an investigational oral GLP-1 monoagonist with ~14.7% mean weight loss at 36 mg (ACHIEVE-1)
- Both drugs are made by Eli Lilly, so price competition between them is unlikely to drive aggressive discounting
- The oral format is the main reason to choose orforglipron once approved; the efficacy gap is the main reason to stay with Zepbound
- Orforglipron is investigational and FormBlends does not sell, supply, or compound it
Direct answer
Zepbound is FDA-approved and meaningfully more effective on average than orforglipron in cross-trial data (22.5% vs 14.7% mean weight loss at top doses). Orforglipron offers the advantage of being a daily pill instead of a weekly injection. Cost is unlikely to be a deciding factor; both are Lilly products and pricing strategy favors parity rather than competition. The question is whether the convenience of an oral medication outweighs the lower mean weight loss.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What each drug is
- Efficacy comparison from the available trials
- The mechanism behind the efficacy gap
- Cost: list price, self-pay, and compounded options
- Insurance coverage outlook
- Format, convenience, and adherence
- Side effects and tolerability
- The patient profiles that favor each
- The contrary view: why orforglipron may win on real-world weight loss
- Decision framework for choosing or switching
- FAQ
- Sources
What each drug is
Zepbound is the brand name for tirzepatide approved for chronic weight management. Same active ingredient as Mounjaro, which is the brand name for tirzepatide approved for type 2 diabetes. Eli Lilly markets both. Zepbound has been available since November 2023.
Tirzepatide is a 39-amino-acid synthetic peptide that binds two receptors: GLP-1 (the same target as semaglutide) and GIP (a related gut hormone receptor). It is injected subcutaneously once weekly. Storage is refrigerated. It is FDA-approved for adults with obesity (BMI 30+) or overweight (BMI 27+) with weight-related comorbidities.
Orforglipron is the development name for Eli Lilly's investigational oral GLP-1 receptor agonist. It is a non-peptide small molecule taken as a once-daily tablet without fasting requirements. It is currently in late-stage development, with positive phase 3 results from ACHIEVE-1 (type 2 diabetes, April 2025) and ATTAIN-1 (obesity, 2025). As of May 2026, it is not FDA-approved.
Both drugs come from the same company. This is unusual and shapes the comparison. Lilly has no incentive to price one drug aggressively below the other; the company captures revenue either way. Patients should not expect competition between Zepbound and orforglipron to drive Lilly to discount Zepbound.
Efficacy comparison from the available trials
SURMOUNT-1 (Jastreboff et al., NEJM 2022) is the pivotal Zepbound trial. ACHIEVE-1 (Lilly press release, April 2025) is the published orforglipron phase 3 data point in diabetes. ATTAIN-1 (the orforglipron obesity trial) has been reported positive but detailed peer-reviewed data is less mature.
| Metric | Zepbound (SURMOUNT-1) | Orforglipron (ACHIEVE-1) |
|---|---|---|
| Trial population | BMI 30+ or BMI 27+ with comorbidity, no diabetes | Type 2 diabetes, elevated BMI |
| Duration | 72 weeks | 72 weeks |
| Lowest active dose | 5 mg/week: ~15% weight loss | 3 mg/day: ~5-6% weight loss |
| Mid active dose | 10 mg/week: ~19.5% weight loss | 12 mg/day: ~9-10% weight loss |
| Top active dose | 15 mg/week: ~22.5% weight loss | 36 mg/day: ~14.7% weight loss |
| Placebo | ~3% weight loss | ~1-2% weight loss |
| Top dose vs placebo (placebo-adjusted) | ~19.5 percentage points | ~12.7 percentage points |
A few notes on interpreting these numbers.
First, the populations differ. Patients with type 2 diabetes generally lose less weight on GLP-1 medications than patients without diabetes, an effect seen across the class. The pure-obesity orforglipron data (ATTAIN-1) will be a more fair comparison once detailed data publish.
Second, the absolute weight loss in SURMOUNT-1 was higher in part because baseline weight was higher. Patients in SURMOUNT-1 had mean baseline weight around 230-240 pounds; ACHIEVE-1 patients had lower baseline weight (around 200-210 pounds is the typical range in diabetes trials).
Third, individual variability is high. A patient at the 75th percentile of orforglipron response can lose more weight than a patient at the 25th percentile of Zepbound response. Averages are useful guides but do not predict individual outcomes.
The mechanism behind the efficacy gap
Why does Zepbound produce more weight loss than orforglipron on average? The leading explanation is the GIP component.
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are two hormones secreted by the small intestine after meals. Both promote insulin secretion in response to glucose. GLP-1 also slows gastric emptying, increases satiety signaling in the brain, and decreases glucagon secretion. GIP has more complex effects: it influences fat metabolism, has effects on the central nervous system, and may improve adipose tissue insulin sensitivity.
Tirzepatide activates both receptors. Orforglipron activates only GLP-1. The dual-receptor mechanism gives tirzepatide access to additional weight-loss-promoting pathways that orforglipron does not engage.
This is not a definitive explanation. Animal studies of GIP receptor agonism produce conflicting results, including both weight gain and weight loss depending on the model. The clinical observation, however, is consistent: dual GLP-1/GIP agonists produce greater mean weight loss than GLP-1 monoagonists. Retatrutide (a triple agonist of GLP-1, GIP, and glucagon receptors) extends this pattern further, with phase 2 weight loss around 24% at 12 mg.
The hierarchy supported by current data:
- Triple agonists (retatrutide): ~24% weight loss at top dose, phase 2
- Dual GLP-1/GIP agonists (tirzepatide): ~22.5% weight loss at top dose, SURMOUNT-1
- GLP-1 monoagonists (semaglutide, orforglipron): ~14.7-14.9% weight loss at top dose
Cost: list price, self-pay, and compounded options
Zepbound pricing as of late 2025:
- List price (pen presentation): approximately $1,059/month
- LillyDirect self-pay program (vial presentation): approximately $499-549/month depending on dose
- Insurance copay (covered plans): typically $25-100/month
- Insurance copay (non-covered plans): full out-of-pocket cost
- Compounded tirzepatide (when available through 503A pharmacies): typically $200-400/month
Orforglipron pricing (speculative, drug not yet approved):
- Likely list price: $800-1,200/month range, similar to Zepbound
- Self-pay program: uncertain whether Lilly will launch a parallel direct-pay program at launch
- Insurance copay: very limited at launch, expanding over 12-24 months
- Compounded versions: not available, because 503A pharmacies cannot compound small-molecule oral drugs in the same way they compound peptides
The patient who currently accesses compounded tirzepatide at $250/month should not assume orforglipron will be cheaper. The compounding pathway is a peptide-specific solution to peptide-specific FDA shortage status. Oral small molecules go through normal commercial channels at branded prices.
Insurance coverage outlook
U.S. insurance coverage for weight-loss medications has been uneven. Medicare specifically excludes obesity drugs under Part D (a statutory exclusion). Many commercial plans have followed suit, citing cost concerns.
Zepbound coverage as of 2025-2026:
- Approximately 50-60% of commercial plans cover it under some conditions
- Coverage often requires prior authorization, BMI documentation, and proof of prior weight loss attempts
- Step therapy may require trying semaglutide or older agents first
- Medicare does not cover it for weight loss; Mounjaro (same drug, different brand) is covered for type 2 diabetes
Orforglipron will face similar coverage dynamics, with one possible wrinkle: payers may prefer the lower-cost diabetes indication first and consider the obesity indication later. If orforglipron approval comes first for type 2 diabetes, patients with diabetes will gain coverage faster than patients without diabetes.
The Medicare coverage situation could shift if Congress modifies the obesity drug exclusion, but this is a multi-year legislative question and should not be assumed.
Format, convenience, and adherence
The clearest differentiator between the two drugs is the format.
Zepbound (tirzepatide):
- Weekly subcutaneous injection
- Pen or vial presentation
- Cold chain storage required
- Injection technique training required at start
- Sharps disposal required
- 52 doses per year
Orforglipron:
- Daily oral tablet
- Room temperature storage
- No fasting requirement
- No injection skills required
- No sharps disposal
- 365 doses per year
Each format favors different patient profiles. The weekly injection minimizes daily friction once the patient is comfortable with injection technique. The daily tablet eliminates the injection step but requires daily consistency.
Adherence data on weekly injections in this class is generally favorable. STEP and SURMOUNT trials reported relatively high adherence rates compared to historic injectable medication adherence. The friction of self-injection is a one-time barrier, not an ongoing weekly barrier, for most patients who clear it.
Adherence data on daily oral medications in chronic conditions tends to be lower than weekly injections in the same conditions, when the comparison has been made. The reason is forgetting: missing one weekly dose is rare; missing daily doses can accumulate without notice.
For patients who simply cannot or will not inject, however, the comparison is irrelevant. Their adherence to an injectable is 0%, regardless of how high the population average is.
Side effects and tolerability
Both drugs share the GLP-1 class safety profile, dominated by gastrointestinal symptoms.
| Side effect | Zepbound (SURMOUNT-1) | Orforglipron (ACHIEVE-1) |
|---|---|---|
| Nausea | ~24-33% | ~16-30% |
| Diarrhea | ~19-23% | ~12-22% |
| Vomiting | ~8-15% | ~8-20% |
| Constipation | ~11-17% | ~5-10% |
| Discontinuation for adverse events | ~6-9% | ~5-10% |
The rates are broadly comparable. Zepbound has more accumulated real-world experience since November 2023, which has refined dose titration and side-effect management practices. Orforglipron has less post-trial experience as of May 2026.
Orforglipron phase 2 data reported small reversible elevations in liver enzymes at higher doses. These were not associated with clinical liver injury in the trials, but the FDA review will scrutinize liver findings carefully. Patients with pre-existing liver disease may want to wait for more long-term data before considering orforglipron, if approved.
Zepbound carries the class-wide boxed warning for thyroid C-cell tumors based on rodent studies. Patients with personal or family history of medullary thyroid carcinoma or MEN-2 should not use it. This warning would likely extend to orforglipron labeling as well.
The patient profiles that favor each
Zepbound fits best when:
- Maximum weight loss is the priority (BMI 35+ or significant metabolic complications)
- The patient tolerates injections without significant aversion
- Insurance coverage or self-pay program access is reasonable
- The patient has not responded to lower-efficacy alternatives
Orforglipron will fit best when:
- Needle aversion has prevented or threatened to derail injectable therapy
- Mild-to-moderate obesity where ~14% weight loss is sufficient
- Frequent travel makes cold-chain storage impractical
- Daily oral routine is more sustainable than weekly injection ritual
A small percentage of patients clearly fit one bucket. Most patients fall in the gray zone and have legitimate reasons to choose either. The conversation with the clinician should weigh medical urgency against personal preference, not impose one option as universally better.
The contrary view: why orforglipron may win on real-world weight loss
Trial data favor Zepbound. Real-world data may favor orforglipron for a subset of patients, and the reason is adherence.
Mean weight loss in trials reflects what happens when patients comply with the protocol. Real-world weight loss reflects what happens with normal adherence patterns. The gap can be substantial.
If 30% of patients prescribed Zepbound discontinue within 6 months due to injection burden, side effects, supply issues, or cost, their real-world weight loss is closer to zero than to 22.5%. If those same patients on orforglipron achieve 70% adherence over the same period, their real-world weight loss may be closer to 10-12% than the trial mean of 14.7%.
In this analysis, the right comparison is not trial mean to trial mean, but expected weight loss times expected adherence:
| Drug | Trial mean | Hypothetical real-world adherence | Expected real-world weight loss |
|---|---|---|---|
| Zepbound | 22.5% | 60% | ~13.5% |
| Orforglipron | 14.7% | 80% | ~11.8% |
These adherence numbers are hypothetical. Real adherence rates depend on patient characteristics, support systems, side-effect management, and many other factors. The point is that the apparent efficacy gap may shrink (or in extreme cases reverse) when adherence is incorporated.
This argument applies most strongly to patients with injection aversion. For patients comfortable with injections, expected adherence is similar between the two drugs, and the trial efficacy hierarchy holds.
Decision framework for choosing or switching
Because orforglipron is not yet approved, current decisions are about whether to start Zepbound now or wait. Future decisions will be about choosing or switching after approval.
If you have not started any GLP-1 therapy:
If your medical situation justifies therapy and you can tolerate injections, start Zepbound or another currently available option. The expected wait for orforglipron is 12-24 months and not guaranteed. Cumulative health burden from untreated obesity is real.
If injection aversion has prevented you from starting and you can wait safely (mild BMI, no major comorbidities), waiting for orforglipron is reasonable. Have a contingency plan if approval slips.
If you are currently on Zepbound:
If you tolerate it well and are responding (weight loss tracking with expected curve, no side effects derailing therapy), there is no clinical reason to switch when orforglipron approves. Stay with what works.
If you are struggling with injection adherence, side effects, or cost: discuss with your clinician whether a future switch to orforglipron makes sense. Document the specific issues you are experiencing.
If you previously tried Zepbound and discontinued:
If you discontinued due to injection burden, orforglipron may be a better fit when approved. If you discontinued due to side effects, the GI side-effect profile of orforglipron is similar; relief is not guaranteed. If you discontinued due to cost, orforglipron will not necessarily be cheaper.
FAQ
Is orforglipron as effective as Zepbound?
In cross-trial data, no. Zepbound (tirzepatide) produced approximately 22.5% mean weight loss in SURMOUNT-1 at the 15 mg dose. Orforglipron produced approximately 14.7% mean weight loss in ACHIEVE-1 at the 36 mg dose. The gap reflects both the dual-receptor mechanism of tirzepatide (GLP-1 plus GIP) and the trial populations. Head-to-head data has not been published.
Will orforglipron be cheaper than Zepbound?
Unclear. Lilly's commercial pattern has been to price new branded weight-loss drugs at parity with existing options (Zepbound launched around $1,000/month list price). Manufacturing cost for an oral small molecule is lower than for an injectable peptide, but list price reflects strategy, not cost-of-goods. Patients should not assume orforglipron will be cheaper out of pocket, especially in the first 12-18 months after launch.
What is the difference between orforglipron and Zepbound?
Zepbound is tirzepatide, an injectable peptide that activates both GLP-1 and GIP receptors (dual agonist). It is FDA-approved for chronic weight management. Orforglipron is an oral small-molecule GLP-1 monoagonist that is investigational and not yet FDA-approved as of May 2026. Both are made by Eli Lilly. The two drugs differ in mechanism, route of administration, and current approval status.
Can I switch from Zepbound to orforglipron when approved?
Once orforglipron is approved, switching will be technically possible under physician supervision. The trade-off is real: you give up the higher mean efficacy of tirzepatide for the convenience of an oral pill. For patients who tolerate Zepbound well and have responded well, the medical case for switching is weak. For patients struggling with injection adherence specifically, the switch may be appropriate.
Will insurance cover orforglipron like Zepbound?
Probably eventually, but not immediately at launch. Insurance coverage for new branded weight-loss drugs typically takes 12-18 months to develop. Zepbound coverage has been uneven across U.S. health plans; many plans exclude weight-loss drugs entirely. Orforglipron will face similar coverage challenges plus the additional uncertainty of being a new molecule.
Why is Zepbound more effective than orforglipron?
Tirzepatide (Zepbound) activates two receptors (GLP-1 and GIP); orforglipron activates one (GLP-1). The GIP component contributes additional weight loss through pathways including enhanced insulin secretion, possible effects on adipose tissue, and broader central nervous system signaling. Mechanism explains most of the efficacy gap in available data.
Is orforglipron available at FormBlends?
No. Orforglipron is investigational and not FDA-approved as of May 2026. FormBlends does not sell, supply, or compound orforglipron. Small-molecule oral drugs cannot be compounded by 503A pharmacies. If approved, orforglipron will be a branded Lilly product available through standard pharmacy channels.
Related guides
- When Will Orforglipron Be Available? The Realistic Timeline
- Zepbound Before and After: A Clinical Timeline of Realistic Weight Loss Results
- Does the Zepbound Injection Hurt? A Realistic Description and the Technique That Makes It Easier
- Will Zepbound Get Cheaper? The Realistic Timeline for Price Drops, Biosimilars, and What You Can Do Now
- When Will Retatrutide Be Available? A Realistic Timeline
- Switching From Tirzepatide to Retatrutide: What's Realistic in 2026
Sources
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205-216. (SURMOUNT-1)
- Eli Lilly and Company. ACHIEVE-1 Phase 3 results, press release. April 17, 2025.
- Eli Lilly and Company. ATTAIN-1 Phase 3 results, press release. 2025.
- Saxena AR, Frias JP, Brown LS, et al. Phase 2 results of orforglipron. The Lancet. 2023;401:1881-1891.
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity. JAMA. 2024;331:38-48. (SURMOUNT-4)
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. NEJM. 2021;385:503-515. (SURPASS-2)
- U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. 2023.
- Eli Lilly and Company. LillyDirect self-pay program pricing information. lillydirect.lilly.com.
- Centers for Medicare and Medicaid Services. Medicare Part D drug coverage exclusions, including statutory exclusion for weight loss drugs.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM. 2021;384:989-1002. (STEP 1)
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity. NEJM. 2023;389:514-526.
Footer disclaimers
Platform Disclaimer. FormBlends offers physician-supervised weight management with FDA-approved and 503A-compounded GLP-1 options. Orforglipron is not on our formulary because it is investigational. Zepbound is referenced for comparison; FormBlends does not have a direct commercial arrangement with Eli Lilly for branded Zepbound, though we provide compounded tirzepatide where regulatory status allows.
Compounded Medication Notice. Compounded tirzepatide is prepared by licensed 503A pharmacies under individual prescription. Compounded tirzepatide is not FDA-approved and not therapeutically interchangeable with brand-name Zepbound. The availability of compounded tirzepatide depends on FDA shortage status, which has changed multiple times. Orforglipron cannot be compounded because oral small molecules are not eligible for the 503A peptide compounding pathway.
Results Disclaimer. Trial weight loss percentages do not predict individual outcomes. Real-world weight loss is influenced by adherence, dose tolerability, lifestyle, and metabolic factors. Cross-trial comparisons between SURMOUNT-1 and ACHIEVE-1 should be interpreted with caution due to differences in patient populations.
Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Orforglipron is a development name for an investigational compound owned by Eli Lilly. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends has no affiliation with Eli Lilly or Novo Nordisk.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →